What Should a Guideline Panel Do When Evidence Is Inconclusive What Should a Guideline Panel Do When Evidence Is Inconclusive? The Case of Treatments for CKD–Mineral and Bone Disorder (CKD-MBD)  Katrin Uhlig, MD, MS  American Journal of Kidney Diseases  Volume 58, Issue 6, Pages 872-875 (December 2011) DOI: 10.1053/j.ajkd.2011.08.001 Copyright © 2011 National Kidney Foundation, Inc. Terms and Conditions

Figure 1 Comparison of guideline recommendations for phosphorus, calcium, and parathyroid hormone (PTH) targets in chronic kidney disease (CKD). Recommendations are numbered as they are in the guideline documents, but wording has been paraphrased or abbreviated as needed. Grades for strength of recommendations are provided in brackets after the recommendations. Grades used for the KDOQI (Kidney Disease Outcomes Quality Initiative) 2003 guideline4: O, opinion-based; E, evidence-based. Grades used for the KDIGO (Kidney Disease: Improving Global Outcomes) 2008 draft guideline: A, strong recommendation; B, moderate recommendation; C, weak recommendation. Grades used for the KDIGO 2009 final guideline3: level 1, strong recommendation; level 2, weak or discretionary recommendation; A, high quality of evidence; B, moderate quality of evidence; C, low quality of evidence; D, very low quality of evidence. KDOQI and KDIGO guidelines are copyright of the National Kidney Foundation and KDIGO, respectively, and are used with permission. American Journal of Kidney Diseases 2011 58, 872-875DOI: (10.1053/j.ajkd.2011.08.001) Copyright © 2011 National Kidney Foundation, Inc. Terms and Conditions